Gomi A, Sakai R, Ogawa S, Shinoda S, Hirai H, Masuzawa T
Department of Surgical Neurology, Jichi Medical School, Tokyo.
Jpn J Cancer Res. 1995 Apr;86(4):342-6. doi: 10.1111/j.1349-7006.1995.tb03062.x.
Studies have shown that homozygous deletion of the cyclin-dependent kinase-4 inhibitor (CDK4I) gene, which is mapped to chromosome 9p21, is frequently observed in various types of human cancers. Here we report that the CDK4I gene was deleted in gliomas. Eight cell lines derived from glioblastomas and samples from 14 patients with various grades of gliomas were examined by Southern blot analysis. We found that the CDK4I gene was deleted in 7 of 8 (87.5%) cell lines and 7 of 9 (78%) samples from high-grade glioma patients, whereas it was deleted in 1 of 5 (20%) low-grade glioma samples. These results suggested that inactivation of the CDK4I gene may play an important role in the progression of human glioma.
研究表明，定位于9号染色体p21区域的细胞周期蛋白依赖性激酶4抑制剂（CDK4I）基因的纯合缺失在多种人类癌症中经常被观察到。在此我们报告，CDK4I基因在胶质瘤中存在缺失。通过Southern印迹分析检测了8种源自胶质母细胞瘤的细胞系以及14例不同级别胶质瘤患者的样本。我们发现，8种细胞系中有7种（87.5%）以及高级别胶质瘤患者的9份样本中有7份（78%）存在CDK4I基因缺失，而低级别胶质瘤样本中5份中有1份（20%）存在该基因缺失。这些结果表明，CDK4I基因的失活可能在人类胶质瘤进展中起重要作用。
